Merck Puffs Up Respiratory Portfolio With EU Rights To Nycomed's Daxas
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck acquires rights to the oral COPD medication in Canada and Europe, where approval appears imminent after Daxas received a positive CHMP nod.